A new, simple, novel, accurate, precise, reliable, rapid and linear reverse phase high-performance liquid chromatography (RP-HPLC) method was developed and fully validated for simultaneous qualitative and quantitative estimation of Rosuvastatin (ROS), Clopidogr el (CLOP) and Aspirin (ASP) in bulk and pharmaceutical dosage form as per International Conference on Harmonization (ICH) guidelines. In the present work, good chromatographic separation was achieved by isocratic method using a Hypersil BDS C18 column (250 mm ×4.6, 5 μm) and a mobile phase consisting of KH2Po4 buffer pH-6.0: acetonitrile in the ratio 60:40, at a flow rate of 1 ml/min. The effluents obtained were monitored at 242nm with the UV-visible detector. The calibration curves obtained were linear (r 2 =0.999) over the concentration range of 7.5-22.5μg/ml and 1-3μg/ml for CLOP, ASP and ROS respectively. A run time of 7.0 minutes for each sample made it possible to analyze more than 200 samples per day. The retention time of ASP, CLOP and ROS was found to be 3.103 min, 4,277 min and 5.707 min respectively. The high recovery values (99%-101%) indicate a satisfactory accuracy. The low percent relative standard deviation (% RSD) values in the precision study rev eal that the method is precise therefore the method can be used for routine monitoring of CLOP, ASP and ROS in industry in the assay of bulk drug and dosage form.
INTRODUCTION
Platelet aggregation and thrombus formation play a critical role in the initiation and development of key complications of acute coronary syndromes (ACSs). HMG-CoA Reductase catalyzes the conversion of HMG-CoA to mevalonic acid, the rate-limiting step in cholesterol biosynthesis and it is used to reduce plasma cholesterol levels and prevent cardiovascular disease (CVD), antiplatelet therapy and antithrombotic therapy have been demonstrated to modify clinical outcome favorably, and recent trials of revascularization in ACSs have demonstrated a reduction in the frequency of major cardiac events [1] [2] [3] . Yet, all effective antithrombotic agents also increase the risk of bleeding. Especially bleeding that result from vascular accessories associated with surgery, including coronary artery bypass grafting (CABG) [4] [5] [6] . Aspirin (ASP) (Fig.1A) is a well-known antithrombotic, antipyretic, analgesic agent. Chemically 2-(acetyloxy) benzoic acid, it is official in USP-NF 7 , BP 8 and IP 9 . It is an antiplatelet agent approved by the Food and Drug Administration, USA, for use in secondary prevention of heart attacks and stroke 10, 11 . Besides it is mainly used as an analgesic, antipyretic, antiinflammatory and antithrombotic agent. Clopidogrel (CLOP) (+)-(S)-methyl2-(2-chlorophenyl)-2-(6,7-dihydrothieno [3,2c] pyridin-5(4H)-yl) acetate ( Fig.1B) , is a new thienopyridine derivative. It is an antiplatelet agent, which selectively inhibits the binding of adenosine diphosphate (ADP) to its platelet receptor and blocks the subsequent ADP-mediated activation of the glycoprotein GPIIb/IIIa complex, thereby inhibiting platelet aggregation 12 . It is official in USP-NF 13 . It has been shown to prevent ischemic stroke, myocardial infarction and vascular disease and has demonstrated its clinical efficacy superior to that of aspirin. Thus, clopidogrel is indicated for the patients with atherosclerosis documented by recent stroke, recent myocardial infraction or cardiovascular disease 14 (Fig.1C ). ROS is a selective and competitive inhibitor of 3-hydroxy-3-methylglutaryl-coenzymeA (HMG-CoA) reductase, the rate-limiting enzyme that converts 3-hydroxy-3-methylglutaryl coenzyme A to mevalonate, a precursor of cholesterol. ROS is a member of the class of statins, used to treat hypercholesterolemia and related conditions and to prevent cardiovascular disease. It increases the number of hepatic LDL (Low Density Lipoprotein) receptors on the cell surface to enhance uptake and catabolism of LDL. Secondly, ROS inhibits hepatic synthesis of VLDL (Very Low Density Lipoprotein), which reduces the total number of VLDL and LDL particles 15 .The combination of aspirin, rosuvastatin and clopidogrel is available in the market as a capsule and tablet dosage form and is choice of drug for treatment of heart attack prevention. Rosumac gold manufactured by Macleod pharmaceuticals was used for RP-HPLC study. The strengths of the drug in the capsule chosen are aspirin 75 mg, rosuvastatin 10 mg and clopidogrel 75 mg. Several analytical methods that have been reported for the estimation of ASP, CLOP and ROS in biological fluids and/or pharmaceutical formulations individually or combination with other drugs include UV, RP-HPLC and HPTLC [16] [17] [18] [19] [20] [21] [22] [23] . Few methods were developed for estimation of these 3 dug in pharmaceutical dosage form by UV and HPLC. But reported method was time consuming, total RT was found to be 16 min [24] [25] [26] . Therefore, an attempt was made to develop a new, rapid and sensitive method for the simultaneous determination of ASP, CLOP and ROS with total run time 7.0 min. To access the reproducibility and wide applicability of the developed method, it was validated as per ICH norm, which is mandatory also 27, 28 . 
MATERIALS AND METHODS

Instrument
Liquid chromatographic system from Shimadzu (LC-20AT) comprising of manual injector, double reciprocating plunger pump LC-20ATVp for constant flow and constant pressure delivery and Photodiode array detector SPD-M20A connected to software LC solution for controlling the instrumentation as well as processing the data generated was used.
Chemicals and reagents
Analytically pure sample of ASP, CLOP and ROS was a generous gift from Yash Pharma Laboratories Pvt. Ltd. Mumbai, India. Potassium di hydrogen phosphates (AR grade), Disodium hydrogen phosphate (AR grade), glacial acetic acid and acetonitrile (HPLC Grade) was purchased from E. Merck Ltd. Worli, Mumbai, India. The 0.45μm nylon filters were purchased from Advanced Micro Devices Pvt. Ltd. Chandigarh, India. All excipients used were of pharmaceutical grade. Triple distilled water was generated in house.
Diluents
A mixture of acetonitrile: phosphate buffer pH-6.0 (40:60 % v/v) was used in RP-HPLC as diluents.
Selection of mobile phase
Initially to estimate ASP, CLOP and ROS simultaneously, number of mobile phases in different ratios was tried.
Taking into consideration the system suitability parameter like RT, tailing factor, number of theoretical plates and HETP, the mobile phase was found to be most suitable for analysis was acetonitrile: phosphate buffer pH-6.0 (40:60 % v/v), run as isocratic system. The mobile phase was filtered through 0.45 m filter paper and then degassed by Sonication. Flow rate employed for analysis was 1 ml/min.
Chromatographic conditions
The isocratic mobile phase consisted of acetonitrile: phosphate buffer pH-6.0 in the ratio of 40:60 (v/v), flowing through the column at a constant flow rate of 1.0 ml/min. A Hypersil BDS C18 column (5 μm, 150mm × 4.60mm) was used as the stationary phase. By considering the chromatographic parameter, sensitivity and selectivity of method for two drugs, 242nm was selected as the detection wavelength for UV-PDA detector. The HPLC system was operated at room temperature 25°C.
Preparation of stock solution
Accurately weighed 100 mg of ASP, CLOP and ROS were transferred into 100 ml volumetric flasks separately and dissolved in 50 ml of diluent, then volume was made up to 100 ml with diluent to get a concentration of 1000μg/ml (Stock-A) for all three drugs.
Preparation of sub stock solution
5 ml of solution was taken from stock-A of ASP, CLOP and ROS and transferred into 50 ml volumetric flask separately and diluted up to 50 ml with diluent to give concentration of 100μg/ml (Stock-B). From stock-B a series of dilution was made in the range of 7.5-22.5μg/ml for ASP, CLOP and 1-3μg/ml for ROS respectively.
System suitability parameters
Separation variable was set and mobile phase was allowed to saturate the column at 1ml/min. After complete saturation of column, six replicates of reference standard, 15μg/ml and 2μg/ml of ASP, CLOP and ROS respectively were injected separately. Peak report and column performance report were recorded at 242 nm for all chromatogram. 
Preparation of calibration curve standards and quality control samples
To establish the linearity of analytical method, a series of dilution ranging from 7.5-22.5μg/ml for ASP, CLOP and 1-3μg/ml for ROS was prepared in the same manner as described above. All the solution were filtered through 0.2 mm membrane filter and injected, chromatograms were recorded at 242 nm and it was repeated for five times. A calibration graph was plotted between the mean peak area and respective concentration and regression equation was derived.
Stability study
Samples prepared for repeatability study were preserved for 24 h at room temperature and analyzed on the following day to test for short-term stability.
Preparation for analysis of capsule formulation
Twenty capsules were taken and their average weight was determined. They are crushed to fine powder; amount equivalent to 10 mg of ROS was taken in 100-ml volumetric flask. The ASP and CLOP present in this amount of tablet powder was 75 mg and the ratios of all three drugs were 10: 75:75. This was than dissolve in 50 ml of diluent by sonication for about 10 minutes. The volume was made upto the mark by diluents and filtered by Whatmann filter paper (no. 41) and the filtrate was used to prepare samples of different concentration. Now all the tablet samples was scanned in multi photometric mode and the concentration of all three drugs were obtained from the equation.
Validation of method
As per ICH guideline the method was validated and following parameters were evaluated.
Linearity
Linearity of ASP, CLOP and ROS was established by response ratios of drug. The response ratios (response factor) were calculated by dividing the AUC with respective concentration. The curve was plotted between response ratios and concentration which shows the good linearity of drugs in the concentration ranging from 7.5-22.5μg/ml for ASP, CLOP and 1-3μg/ml for ROS respectively.
Specificity
Specificity of the method was carried out to assess unequivocally the analyte presence of the components that might be expected to be present, such as impurities, degradation products and matrix components.
Precision
Precision was determined by repeatability, Intermediate precision and reproducibility of all three drugs.
Repeatability
The repeatability was performed for five replicate at five concentrations in linearity range for ASP, CLOP and ROS that indicates the precision under the same operating condition over short interval time.
Intermediate precision
Day to day precision
Intermediate precision was also performed within laboratory variation on different days for all three drugs simultaneously in five replicate at five concentrations.
Analyst-to-analyst precision
Analyst to analyst variation was performed by different analyst in five replicate at five concentrations.
Reproducibility
The reproducibility was performed by chemical to chemical (use of Rankem chemicals in place of Merck chemicals) variation in five replicate at five concentrations.
Accuracy (% recovery)
This study was carried out using pre analyzed tablet solution. A definite concentration of pure drug was added (80 %, 100 % and 120 % level) and then recovery was studied. A pre analyzed tablet solution containing 7.5μg/ml of ASP 1μg/ml of ROS and 7.5μg/ml of CLOP were taken in 10 ml volumetric flasks and known concentrations of pure drug solution was added to them, which were prepared from standard stock solution of ASP, CLOP and ROS. It was repeated at 5 concentrations and 3 replicate levels. Calculation was done from the label claim and the average weight of the final product.
Robustness
As per ICH norms, small, but deliberate variations in flow rate, pH and concentration of the mobile phase were made to check the method's capacity to remain unaffected. 
LOD and LOQ
The LOD and LOQ of developed method were calculated based on the standard deviation of response and slope of the linearity curve.
RESULTS AND DISCUSSION
Method development
The goal of this work was to develop and validate a simple, rapid and sensitive assay method for the quantitative determination of ASP, CLOP and ROS from capsule dosage form. Initially to estimate ASP, CLOP and ROS simultaneously number of mobile phases in different ratios was tried. Taking into consideration the system suitability parameter (Table 1) like RT, tailing factor, number of theoretical plates and HETP, the mobile phase was found to be most suitable for analysis was acetonitrile: KH2Po4 buffer pH-6.0 (40:60 % v/v), run as isocratic system. The mobile phase was filtered through 0.45 m filter paper and then degassed by sonication. Flow rate employed for analysis was 1.0 ml/min. Separation variable ( Table 2 ) was set and mobile phase was allowed to saturate the column at 1.0 ml/min. After complete saturation of column, six replicates of reference standard, 15μg/ml of ASP, CLOP and 2μg/ml of ROS were injected separately. Peak report and column performance report were recorded. The chromatogram was recorded at 242 nm Figure 2 . The peak areas were plotted against the corresponding concentrations to obtain the calibration graph Figure 3 -5. The result of their optical characteristics and linearity data of all three drugs has been reported in the Table 3 . 
Method Validation
Linearity
The proposed method was found to be linear in the range of 7.5-22.5μg/ml and 1-3μg/ml for ASP, CLOP and ROS respectively with correlation coefficient 0.9998, 0.9997 and 0.9997 for ASP, CLOP and ROS respectively. Linearity of ASP, CLOP and ROS were established by response ratios of drug. Response ratio of three drugs was calculated by dividing the absorbance or peak area with respective concentration (Table 4 ).
Specificity
Specificity of the method was carried out to assess unequivocally the analyte presence of the components that might be expected to be present, such as matrix components. The result of specificity is shown in Figure 6 and Figure 7 as compare to blank, there was no interference seen in chromatogram.
Precision
Precision of the methods was studied at three levels as at repeatability, intermediate precision (Day to Day and analyst to analyst) and reproducibility (Table 5 ).
Accuracy
The validity and reliability of proposed methods were assessed by recovery studies. The recovery of added standards (80 %, 100 % and 120 %) was found at five replicate and five concentrations level. The values of % mean just close to 100, SD and % RSD were less than 2 which indicate the accuracy of method. Result of recovery study is shown in Table 6 .
Robustness
The robustness of developed method was checked by changing in the deliberate variation in solvent. Result of robustness is shown in Table 7 -9.
LOD and LOQ
Detection limit and Quantitation limit of described method were observed as 0.300 mg/ml and 0.909 µg/ml for ASP, 0.372 µg/ml and 1.127 µg/ml for CLOP, 0.050 µg/ml and 0.153 µg/ml for ROS, based on the SD of response and slope, which meet the requirement of new method.
Assay of marketed formulation
The results of the analysis of capsule formulation (Rosumac-Gold) were reported. The assay value of ASP, CLOP and ROS were close to 100, SD and % RSD are less than 2 which indicate that the no interference of excipient in the estimation of ASP, CLOP and ROS was observed. The statistical evaluation of tablet analysis by methods has been reported in Table 10 . 
CONCLUSION
In summary, we have developed and validated a rapid, specific, reproducible RP-HPLC method to quantify ASP, CLOP and ROS simultaneously. So far no published methods are available for the simultaneous quantification of these three drugs in capsule dosage form. To the best of our knowledge, this is the first time that all three analytes were estimated simultaneously in any of the capsule dosage form. The cost-effectiveness, simplicity of the assay is that sample turnover rate of less than 7 minutes per sample; make it an attractive procedure in high-throughput analysis of ASP, CLOP and ROS. From the results of all the validation parameters, we can conclude that the developed method can be useful for routine analysis and therapeutic drug monitoring with desired precision and accuracy.
